Theralase Technologies Inc.
TLTFF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.29 | 0.34 | -0.14 | 3.38 |
| FCF Yield | -1.44% | -2.19% | -0.89% | -0.75% |
| EV / EBITDA | -52.12 | -53.65 | -33.18 | -73.65 |
| Quality | ||||
| ROIC | -72.22% | -64.11% | -109.40% | -39.20% |
| Gross Margin | 56.81% | 54.00% | 14.58% | 64.12% |
| Cash Conversion Ratio | 0.68 | 1.07 | 0.24 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.02% | 1.80% | -5.76% | -3.18% |
| Free Cash Flow Growth | 32.09% | -150.79% | 11.19% | 66.36% |
| Safety | ||||
| Net Debt / EBITDA | -0.25 | -0.22 | -0.10 | -0.03 |
| Interest Coverage | -246.43 | -213.21 | -297.40 | -170.71 |
| Efficiency | ||||
| Inventory Turnover | 0.25 | 0.19 | 0.15 | 0.27 |
| Cash Conversion Cycle | -146.44 | -149.19 | -35.49 | 231.82 |